Centocor’s BLA for ustekinumab for the treatment of plaque psoriasis has been delayed by three months to December 2008. Centocor filed the BLA late in 2007.     The FDA extended the review period in order to review amendments to the application provided by Centocor within the last three months. The FDA has not requested additional clinical trials.     In June, the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) unanimously recommended ustekinumab for approval...